<DOC>
	<DOCNO>NCT02399345</DOCNO>
	<brief_summary>This open-label study evaluate safety efficacy co-formulated ombitasvir/paritaprevir/ritonavir dasabuvir co-administered sofosbuvir without ribavirin administer either 4 6 week treatment naive adult chronic HCV-genotype 1 infection without cirrhosis</brief_summary>
	<brief_title>Ombitasvir/Paritaprevir/Ritonavir Dasabuvir Co-Administered With Sofosbuvir With Without Ribavirin Treatment-Naive HCV Genotype 1-Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>1 . Male female least 18 year age time screen 2 . Chronic Hepatitis C virus ( HCV ) infection prior study enrollment 3 . Screening laboratory result central clinical laboratory indicate HCV genotype 1 infection 4 . Absence cirrhosis advance bridging fibrosis 1 . Positive test result hepatitis B surface antigen ( HbsAg ) human immunodeficiency virus ( HIV ) positive immunoassay 2 . Clinically significant abnormality comorbidities , HCV infection , make subject unsuitable candidate study treatment Ribavirin ( RBV ) opinion investigator 3 . Any current past clinical evidence cirrhosis ascites esophageal varix , prior biopsy show cirrhosis advance bridging fibrosis , e.g. , Metavir score &gt; 2 Ishak score &gt; 3 4 . Use medication contraindicate ombitasvir/paritaprevir/ritonavir , dasabuvir , sofosbuvir , ribavirin ( RBV ; receive RBV ) , within 2 week 10 halflives whichever longer , prior study drug administration 5 . Current enrolment another clinical study , previous enrolment study , previous use investigational commercially available antiHCV agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Treatment naive</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
</DOC>